Jul 10, 2025
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS)
Jul 03, 2025
Quebec implements public reimbursement of Pluvicto® - a defining milestone for radioligand therapy in Canada
Jun 18, 2025
Health Canada approves Novartis' KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence
Apr 14, 2025
Fabhalta® (iptacopan capsules), first oral treatment for adult patients with PNH, now available in Canada
Mar 07, 2025
Alberta sets a new standard for advanced prostate cancer treatment with public reimbursement of Pluvicto(TM)
Feb 13, 2025
Novartis receives Health Canada approval for Fabhalta® oral treatment for adult patients with PNH
Feb 03, 2025
Nova Scotia shows leadership in publicly reimbursing Pluvicto(TM) for eligible patients with advanced prostate cancer
Dec 13, 2024
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO(TM)
Dec 04, 2024
Novartis Canada awards more than $680,000 to community-based programs aimed at advancing health equity
Aug 20, 2024
Novartis celebrates Canada-wide implementation of newborn screening for spinal muscular atrophy
Jul 08, 2024
Novartis Canada launches $500,000 funding initiative to improve health equity in Canada
May 27, 2024
NOVARTIS CANADA AND CLARIUS MOBILE HEALTH CHALLENGE STANDARD OF CARE FOR PSORIATIC ARTHRITIS WITH NEW PARTNERSHIP
Dec 16, 2020
Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)1
Aug 13, 2020
PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer
Apr 16, 2020
Health Canada approves an extended indication for KISQALI® (ribociclib) in combination treatment
Mar 03, 2020
Novartis receives Health Canada approval for Mayzent(TM) (siponimod) to treat secondary progressive multiple sclerosis with active disease